Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2016 Nov 14;23(2):318–324. doi: 10.1016/j.bbmt.2016.11.008

Figure 1.

Figure 1

(A) Cumulative incidence (CI) of acute graft-versus-host disease (aGVHD); (B) CI of chronic GVHD (cGVHD); (C) CI of non-relapse mortality (NRM) and relapse rate; (D) Disease-free survival (DFS) and overall survival (OS); (E) DFS by age subgroup in years; (F) DFS by median time from diagnosis to transplantation; (G) DFS by comorbidity score; (H) DSF by presence (Yes) or absence (No) of extramedullary disease); and (I) DFS by disease status prior to transplant. Abbreviations: CR1, patients in first complete remission; CR2, patients in second complete remission; other, all other patients with primary refractory disease or beyond CR2.